Proair hfa steroid

Pediatric Patients 4 to 11 Years of Age: In a 3-week, randomized, double-blind, placebo-controlled trial, the same formulation of albuterol as in PROAIR HFA Inhalation Aerosol (50 patients) was compared to a matched placebo HFA inhalation aerosol (45 patients) in asthmatic children 4 to 11 years of age at a dose of 180 mcg albuterol four times daily. Serial FEV 1 measurements, expressed as the maximum percent change from test-day baseline in percent predicted FEV 1 at Day 1 and at Day 22 observed within two hours post-dose, demonstrated that two inhalations of HFA albuterol sulfate produced significantly greater improvement in FEV 1 over the pre-treatment value than the matched placebo.

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of albuterol inhalation aerosol (eg, Proair ® HFA) in children 4 years of age and older, albuterol inhalation powder (eg, Proair ® Respiclick®) in children 4 years of age and older, and albuterol inhalation solution (eg, Accuneb ®) in children 2 years of age and older. However, safety and efficacy have not been established for the albuterol inhalation aerosol and albuterol inhalation powder in children younger than 4 years of age, and albuterol inhalation solution in children younger than 2 years of age.

Proair hfa steroid

proair hfa steroid

Media:

proair hfa steroidproair hfa steroidproair hfa steroidproair hfa steroid

http://buy-steroids.org